Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-03-19

Clinical Trial Update: Study to Evaluate the Clinical Efficacy of Streptococcus Dentisani CECT 7746 in Caries Risk Reduction [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the probiotic Streptococcus dentisani CECT 7746 for reduction of caries risk has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Streptococcus dentisani CECT 7746

Snippet

Sponsor: AB Biotics, SA | Conditions: Caries | Phase 1 | Status: COMPLETED